J-Pharma

520A.TTSE GROWTHPharmaceutical

Key numbers · FY ended 2026-03

Operating income−¥3.7bn—Total assets¥4.8bn+66.7% YoY EPS (basic)¥-195.08-6.0% YoY

Full financial history and reports →

Stock price520A · View chart ↗

Open the price chart on TradingView.

Latest filings

Thu, May 14 · JST1 filing

16:50MATERIALJ-Pharma · Event with a material impact on financial position

Wed, Apr 1 · JST1 filing

11:365% STAKEJ-Pharma · JIC Venture Growth Investments Co., Ltd. · 11.34%new 11.34%

Tue, Mar 31 · JST1 filing

15:325% STAKEJ-Pharma · Eight Roads Ventures Japan II LP · 10.88%new 10.88%

Thu, Mar 26 · JST1 filing

11:245% STAKEJ-Pharma · Newton Biocapital I, pricaf privee de droit belge · 6.87%new 6.87%

All filings →

Major holders (5%+) · 3

Holder	Stake	Change	Filed
JIC Venture Growth Investments Co., Ltd.	11.34%	—	2026-04-01
Eight Roads Ventures Japan II LP	10.88%	—	2026-03-31
Newton Biocapital I, pricaf privee de droit belge	6.87%	—	2026-03-26

Each holder's own ratio from its most recent large-shareholding report.